Last reviewed · How we verify
[Lu-177]-PNT2002
[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy.
[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy. Used for Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), SSTR2-positive neuroendocrine tumors.
At a glance
| Generic name | [Lu-177]-PNT2002 |
|---|---|
| Also known as | [Lu-177]-PSMA-I&T, LY4187525 |
| Sponsor | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company |
| Drug class | Somatostatin receptor 2 (SSTR2) targeted radiopharmaceutical |
| Target | Somatostatin receptor 2 (SSTR2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PNT2002 is a somatostatin receptor 2-targeted radiopharmaceutical that binds to SSTR2-expressing neuroendocrine tumors and delivers localized beta radiation via lutetium-177. This theranostic approach allows both imaging and therapeutic targeting of SSTR2-positive tumors, with the radioactive payload inducing DNA damage and cell death in tumor cells while minimizing systemic exposure.
Approved indications
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- SSTR2-positive neuroendocrine tumors
Common side effects
- Hematologic toxicity (anemia, thrombocytopenia, leukopenia)
- Nausea and vomiting
- Fatigue
- Renal toxicity